Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR01180
|
|||||
Drug Name |
Vincamine
|
|||||
Synonyms |
(+)-Vincamine; 1617-90-9; Anasclerol; Anasclerol (base); Angiopac; Arteriovinca; Decincan; Devincan; Devinkan; Equipur; HSDB 7150; Methyl vincaminate; Minorin; Minorine; Monorin; Novicet; Ocu-vinc; Oxygeron; Perval; Pervincamine; Pervone; Tripervan; UNII-996XVD0JHT; Vinca; Vinca-Ecobi; Vinca-Minor; Vincachron; Vincadar; Vincafolina; Vincafor; Vincagil; Vincamidol; Vincamin; Vincamina [DCIT]; Vincamine [INN:BAN:DCF]; Vincamine base; Vincaminum [INN-Latin]; Vincapan; Vincapront; Vincasaunier; Vincimax; Vinkametrin; Vinodrel retard; vincamine
|
|||||
Drug Type |
Small molecular drug
|
|||||
Structure |
|
|||||
3D MOL | 2D MOL | |||||
Formula |
C21H26N2O3
|
|||||
Canonical SMILES |
CCC12CCCN3C1C4=C(CC3)C5=CC=CC=C5N4C(C2)(C(=O)OC)O
|
|||||
InChI |
InChI=1S/C21H26N2O3/c1-3-20-10-6-11-22-12-9-15-14-7-4-5-8-16(14)23(17(15)18(20)22)21(25,13-20)19(24)26-2/h4-5,7-8,18,25H,3,6,9-13H2,1-2H3/t18-,20+,21+/m1/s1
|
|||||
InChIKey |
RXPRRQLKFXBCSJ-GIVPXCGWSA-N
|
|||||
CAS Number |
CAS 1617-90-9
|
|||||
Pharmaceutical Properties | Molecular Weight | 354.4 | Topological Polar Surface Area | 54.7 | ||
Heavy Atom Count | 26 | Rotatable Bond Count | 3 | |||
Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 4 | |||
XLogP |
2.9
|
|||||
PubChem CID | ||||||
PubChem SID |
10321482
, 103763450
, 103913976
, 104336990
, 11442
, 11466299
, 11467419
, 11486097
, 121362779
, 124812111
, 124896567
, 126623137
, 126648205
, 134224874
, 134979517
, 135652725
, 136043617
, 137006675
, 143315335
, 144204895
, 144212285
, 14901040
, 152035890
, 15928943
, 24712294
, 24851332
, 29204673
, 29283340
, 3137905
, 47573493
, 47646670
, 47795170
, 48094657
, 48243519
, 48394062
, 48424315
, 49698413
, 50063094
, 50227572
, 56463369
, 57328977
, 589983
, 605104
, 81092948
, 8161547
, 85789347
, 90455313
, 92125108
, 93619689
, 96025360
|
|||||
TTD Drug ID |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.